中国人兽共患病学报2017，Vol.33Issue(3)：222-227,6.DOI:10.3969/j.issn.1002-2694.2017.03.006
基于改良型痘苗病毒安卡拉株载体的新型流感疫苗研究进展
Advance in the development of modified vaccinia virus Ankara (MVA)vectors for novel influenza vaccines
尹元 1王伟灵1
作者信息
- 1. 上海中医药大学附属上海市中西医结合医院检验科,上海200082
- 折叠
摘要
Abstract
Influenza,caused by influenza virus,is a respiratory infectious disease with a serious hazard to human health.Prevention of influenza through vaccine development is the most effective strategy.It is important to build a rapid response platform for research and production of influenza vaccine.As virus vectors,live vaccine provides a new prevention and treatment way for infectious disease.Modified vaccinia virus Ankara(MVA) is a replication-deficient viral vector that is safe and can encode one or more foreign antigens and induce humoral and cellular immune response.MVA holds great promise as a vaccine platform.In this review,we discuss the use of MVA for vaccine development against influenza virus.关键词
流感病毒/改良型痘苗病毒安卡拉株/病毒载体疫苗Key words
influenza virus/modified vaccinia virus Ankara/viral vector vaccine分类
医药卫生引用本文复制引用
尹元,王伟灵..基于改良型痘苗病毒安卡拉株载体的新型流感疫苗研究进展[J].中国人兽共患病学报,2017,33(3):222-227,6.
